Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Eli Lilly’s Alzheimer's drug fails in phase 3 trial Eli Lilly and Company said that its solanezumab monoclonal antibody designed to treat dimentia associated with Alzheimer’s disease (AD) did not meet its primary endpoint in a phase 3 study. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Aclaris starts phase 1 trial for ATI-50001 to treat alopecia totalis and alopecia universalis
Aclaris Therapeutics' investigational new drug (IND) application for ATI-50001, an orally administered investigational Janus Kinase (JAK) inhibitor, for the potential treatment of alopecia totalis and alopecia universalis has cleared the 30-day review period by the US Food and Drug Administration, allowing the company to go ahead with its planned Phase 1 clinical trial
Contract Research & Services > Clinical Trials > News
Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib
Cascadian Therapeutics announced that after a recent meeting with the US Food and Drug Administration (FDA) and discussions with the Company's external Steering Committee, it has amended the HER2CLIMB Phase 2 clinical trial of tucatinib (also known as ONT-380) by increasing the sample size so that, if successful, the trial could serve as a single pivotal study to support registration.
Production & Manufacturing > Process & Production > News

Contract Research

Research shows flickering lights could be used in Alzheimer's treatment
By PBR Staff Writer
Researchers at the Massachusetts Institute of Technology (MIT) have discovered a non-invasive visual stimulation technique that can be potentially used for treating Alzheimer’s disease.
Oxford BioMedica partners with Orchard Therapeutics
Gene and cell therapy firm Oxford BioMedica has partnered with Orchard Therapeutics, a clinical-stage biotechnology firm dedicated to bringing transformative ex-vivo gene therapies to patients with severe and life-threatening orphan diseases.
Contract Research & Services > Contract Research > News

Contract Services

Sermonix signs licensing deal to further explore lasofoxifene for breast cancer treatment
Sermonix Pharmaceuticals has signed a licensing agreement to gain exclusive rights to Duke University intellectual property related to the use of lasofoxifene, its lead investigational drug, in the treatment of endocrine-resistant breast cancer.
Contract Research & Services > Contract Services > News
Purdue Pharma, AnaBios partner to advance research for non-opioid, non-NSAID compounds
Purdue Pharma and AnaBios have partnered to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain.
Contract Research & Services > Contract Services > News